Plasma procalcitonin is associated with all-cause and cancer mortality in apparently healthy men: a prospective population-based study

被引:16
作者
Cotoi, Ovidiu S. [1 ]
Manjer, Jonas [2 ]
Hedblad, Bo [2 ]
Engstrom, Gunnar [2 ]
Melander, Olle [2 ]
Schiopu, Alexandru [2 ,3 ]
机构
[1] Univ Med & Pharm Tirgu Mures, Dept Cellular & Mol Biol, Targu Mures, Romania
[2] Lund Univ, Dept Clin Sci, Lund, Sweden
[3] Skane Univ Hosp, Cardiol Clin, Malmo, Sweden
来源
BMC MEDICINE | 2013年 / 11卷
关键词
Procalcitonin; Inflammation; Cancer; Cardiovascular disease; CRP; Mortality; C-REACTIVE PROTEIN; SYSTEMIC INFLAMMATION; SEPSIS; INFECTION; DIAGNOSIS; PEPTIDES; SWEDEN; COHORT; RISK; GENE;
D O I
10.1186/1741-7015-11-180
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The inflammatory mediator procalcitonin (PCT) has previously been associated with prognosis in myocardial infarction, cancer and sepsis patients. The importance of PCT in the general population is currently unknown. Our aim was to assess the relationship between plasma PCT and the risk of all-cause and cause-specific mortality in apparently healthy individuals with no previous history of cardiovascular disease or cancer. Methods: We performed a prospective, population-based study on 3,322 individuals recruited from the Malmo Diet and Cancer cohort, with a median follow-up time of 16.2 years. Plasma PCT, high-sensitivity C-reactive protein (hsCRP), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides and cystatin C were measured at baseline and a thorough risk factor assessment was performed for all subjects. The primary end-points of the study were all-cause mortality, cancer mortality and cardiovascular mortality. Results: Men had higher PCT levels compared to women. In Cox proportional hazard models adjusted for age, sex, hypertension, diabetes, plasma lipids, renal function, body mass index and smoking, baseline PCT was associated with all-cause mortality and cancer mortality in men. The hazard ratio (HR) for men with PCT levels within the highest compared with the lowest quartile was 1.52 (95% confidence interval (CI) 1.07 to 2.16; P = 0.024) for all-cause mortality and 2.37 (95% CI 1.36 to 4.14; P = 0.006) for cancer mortality. Additionally, men with increased plasma PCT were found to be at a higher risk to develop colon cancer (HR per 1 SD increase = 1.49 (95% CI 1.13 to 1.95); P = 0.005). In multivariate Cox regression analyses with mutual adjustments for PCT and hsCRP, PCT was independently associated with cancer death (HR per 1 SD increase = 1.28 (95% CI 1.10 to 1.49); P = 0.001) and hsCRP with cardiovascular death (HR per 1 SD increase = 1.42 (95% CI 1.11 to 1.83); P = 0.006) in men. We found no significant correlations between baseline PCT or hsCRP and incident cancer or cardiovascular death in women. Conclusions: We disclose for the first time important independent associations between PCT and the risk for all-cause and cancer mortality in apparently healthy men. Our findings warrant further investigation into the mechanisms underlying the relationship between PCT and cancer.
引用
收藏
页数:9
相关论文
共 37 条
  • [1] Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer
    Allin, Kristine H.
    Nordestgaard, Borge G.
    [J]. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2011, 48 (04) : 155 - 170
  • [2] HIGH SERUM PROCALCITONIN CONCENTRATIONS IN PATIENTS WITH SEPSIS AND INFECTION
    ASSICOT, M
    GENDREL, D
    CARSIN, H
    RAYMOND, J
    GUILBAUD, J
    BOHUON, C
    [J]. LANCET, 1993, 341 (8844) : 515 - 518
  • [3] Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target
    Becker, Kenneth L.
    Snider, Richard
    Nylen, Eric S.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2010, 159 (02) : 253 - 264
  • [4] Clinical review 167 -: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis:: A journey from calcitonin back to its precursors
    Becker, KL
    Nylén, ES
    White, JC
    Müller, B
    Snider, RH
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (04) : 1512 - 1525
  • [5] DESIGN AND FEASIBILITY
    BERGLUND, G
    ELMSTAHL, S
    JANZON, L
    LARSSON, SA
    [J]. JOURNAL OF INTERNAL MEDICINE, 1993, 233 (01) : 45 - 51
  • [6] Brunkhorst FM, 2000, INTENS CARE MED, V26, pS148, DOI 10.1007/BF02900728
  • [7] Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults
    Calle, EE
    Rodriguez, C
    Walker-Thurmond, K
    Thun, MJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (17) : 1625 - 1638
  • [8] Charbonney E, 2006, Rev Med Suisse, V2, P2852
  • [9] Inflammation and cancer
    Coussens, LM
    Werb, Z
    [J]. NATURE, 2002, 420 (6917) : 860 - 867
  • [10] Franks AL, 2012, ANTICANCER RES, V32, P1119